Promising Mesenchymal Stem Cell Intervention for Relieving Cardiac Recovery against Cardiotoxic Injury Modeling with Doxorubicin: A Novel Therapeutic Approach

Doxorubicin (DOX), a commonly used anti-neoplastic agent, has been associated with significant cardiotoxic effects, which limit its clinical utility. Recent studies suggest that mesenchymal stem cells (MSCs) may offer therapeutic potential in mitigating DOX-induced cardiotoxicity through their regen...

Full description

Saved in:
Bibliographic Details
Main Authors: Ozgermen Deva Basak Boztok, Haydardedeoglu Ali Evren, Yavuz Orhan
Format: Article
Language:English
Published: Sciendo 2025-06-01
Series:Acta Veterinaria
Subjects:
Online Access:https://doi.org/10.2478/acve-2025-0012
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849721446122651648
author Ozgermen Deva Basak Boztok
Haydardedeoglu Ali Evren
Yavuz Orhan
author_facet Ozgermen Deva Basak Boztok
Haydardedeoglu Ali Evren
Yavuz Orhan
author_sort Ozgermen Deva Basak Boztok
collection DOAJ
description Doxorubicin (DOX), a commonly used anti-neoplastic agent, has been associated with significant cardiotoxic effects, which limit its clinical utility. Recent studies suggest that mesenchymal stem cells (MSCs) may offer therapeutic potential in mitigating DOX-induced cardiotoxicity through their regenerative properties. This study aimed to evaluate the cardioprotective effects of fetal kidney-derived mesenchymal stem cells (FKD-MSCs) in a DOX-induced cardiotoxicity rat model. Thirty male Sprague-Dawley rats were divided into three groups: control, sham, and treatment. DOX (10 mg/kg) was administered to the sham and treatment groups to induce cardiotoxicity. The treatment group received intraperitoneal FKD-MSCs (2 × 106) three times at weekly intervals post-DOX administration. Immunohistochemical analyses were conducted to assess cardiac recovery. The 5-bromo-2-deoxyuridine (BrdU) labeling technique was used to track FKD-MSC localization in the cardiac tissue. The immunohistochemical findings demonstrated a significant improvement in the treatment group compared to the sham group. The BrdU-labeled FKD-MSCs were predominantly localized in cardiac muscle tissues, indicating their successful homing and integration into damaged cardiac regions. The results of the study indicate that FKD-MSCs significantly attenuated DOX-induced cardiotoxicity in rats, suggesting their potential as a novel therapeutic approach for cardioprotection. Further studies are warranted to investigate their clinical applications in managing chemotherapy-induced cardiotoxicity.
format Article
id doaj-art-46df106fe0594d40a0df759e1448aef0
institution DOAJ
issn 1820-7448
language English
publishDate 2025-06-01
publisher Sciendo
record_format Article
series Acta Veterinaria
spelling doaj-art-46df106fe0594d40a0df759e1448aef02025-08-20T03:11:39ZengSciendoActa Veterinaria1820-74482025-06-0175213915010.2478/acve-2025-0012Promising Mesenchymal Stem Cell Intervention for Relieving Cardiac Recovery against Cardiotoxic Injury Modeling with Doxorubicin: A Novel Therapeutic ApproachOzgermen Deva Basak Boztok0Haydardedeoglu Ali Evren1Yavuz Orhan21Aksaray University, Faculty of Veterinary Medicine, Department of Surgery, Turkey2Aksaray University, Faculty of Veterinary Medicine, Department of Internal Medicine, Turkey3Dokuz Eylül University, Faculty of Veterinary Medicine, Department of Pathology.Doxorubicin (DOX), a commonly used anti-neoplastic agent, has been associated with significant cardiotoxic effects, which limit its clinical utility. Recent studies suggest that mesenchymal stem cells (MSCs) may offer therapeutic potential in mitigating DOX-induced cardiotoxicity through their regenerative properties. This study aimed to evaluate the cardioprotective effects of fetal kidney-derived mesenchymal stem cells (FKD-MSCs) in a DOX-induced cardiotoxicity rat model. Thirty male Sprague-Dawley rats were divided into three groups: control, sham, and treatment. DOX (10 mg/kg) was administered to the sham and treatment groups to induce cardiotoxicity. The treatment group received intraperitoneal FKD-MSCs (2 × 106) three times at weekly intervals post-DOX administration. Immunohistochemical analyses were conducted to assess cardiac recovery. The 5-bromo-2-deoxyuridine (BrdU) labeling technique was used to track FKD-MSC localization in the cardiac tissue. The immunohistochemical findings demonstrated a significant improvement in the treatment group compared to the sham group. The BrdU-labeled FKD-MSCs were predominantly localized in cardiac muscle tissues, indicating their successful homing and integration into damaged cardiac regions. The results of the study indicate that FKD-MSCs significantly attenuated DOX-induced cardiotoxicity in rats, suggesting their potential as a novel therapeutic approach for cardioprotection. Further studies are warranted to investigate their clinical applications in managing chemotherapy-induced cardiotoxicity.https://doi.org/10.2478/acve-2025-0012doxorubicinstem cellscardiotoxicrecovery
spellingShingle Ozgermen Deva Basak Boztok
Haydardedeoglu Ali Evren
Yavuz Orhan
Promising Mesenchymal Stem Cell Intervention for Relieving Cardiac Recovery against Cardiotoxic Injury Modeling with Doxorubicin: A Novel Therapeutic Approach
Acta Veterinaria
doxorubicin
stem cells
cardiotoxic
recovery
title Promising Mesenchymal Stem Cell Intervention for Relieving Cardiac Recovery against Cardiotoxic Injury Modeling with Doxorubicin: A Novel Therapeutic Approach
title_full Promising Mesenchymal Stem Cell Intervention for Relieving Cardiac Recovery against Cardiotoxic Injury Modeling with Doxorubicin: A Novel Therapeutic Approach
title_fullStr Promising Mesenchymal Stem Cell Intervention for Relieving Cardiac Recovery against Cardiotoxic Injury Modeling with Doxorubicin: A Novel Therapeutic Approach
title_full_unstemmed Promising Mesenchymal Stem Cell Intervention for Relieving Cardiac Recovery against Cardiotoxic Injury Modeling with Doxorubicin: A Novel Therapeutic Approach
title_short Promising Mesenchymal Stem Cell Intervention for Relieving Cardiac Recovery against Cardiotoxic Injury Modeling with Doxorubicin: A Novel Therapeutic Approach
title_sort promising mesenchymal stem cell intervention for relieving cardiac recovery against cardiotoxic injury modeling with doxorubicin a novel therapeutic approach
topic doxorubicin
stem cells
cardiotoxic
recovery
url https://doi.org/10.2478/acve-2025-0012
work_keys_str_mv AT ozgermendevabasakboztok promisingmesenchymalstemcellinterventionforrelievingcardiacrecoveryagainstcardiotoxicinjurymodelingwithdoxorubicinanoveltherapeuticapproach
AT haydardedeoglualievren promisingmesenchymalstemcellinterventionforrelievingcardiacrecoveryagainstcardiotoxicinjurymodelingwithdoxorubicinanoveltherapeuticapproach
AT yavuzorhan promisingmesenchymalstemcellinterventionforrelievingcardiacrecoveryagainstcardiotoxicinjurymodelingwithdoxorubicinanoveltherapeuticapproach